Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma

NCT05968768 is registered in ClinicalTrials.gov with Anna Raciborska as lead sponsor.

NCT NCT05968768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05968768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma
Lead sponsor
Anna Raciborska
Phase
Phase 2
Overall status
Recruiting
Start date
October 24, 2023
Completion date
July 31, 2028
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma